



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO-1449**

ATTY. DOCKET NO.
1662/60707

SERIAL NO.
10/621,623

APPLICANT
Gennady NISNEVICH et al.

FILING DATE
July 16, 2003

GROUP 1626
To Be Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,270,317*	December 14, 1993	Bernhart et al.	7	—	
	5,559,233*	September 24, 1996	Bernhart et al.	—	—	
	5,629,331*	May 13, 1997	Caron et al.	—	—	
	5,128,355*	July 7, 1992	Carini et al.	—	—	

* A copy is not enclosed since it was cited in the specification of the present application which was filed after June 30, 2003.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER <u>Laura F. Stockton</u>	DATE CONSIDERED <u>1/20/06</u>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/60707	SERIAL NO. 10/621,623
	APPLICANT Ben-Zion DOLITZKY et al.	
	FILING DATE July 16, 2003	GROUP 1614 1626

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLAS S	SUBCLAS S	FILING DATE*

* A copy is not enclosed since it was cited in the specification of the present application which was filed after June 30, 2003.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA- TION	
						YES	NO
	WO 99 38847 A	August 5, 1999	PCT	—	—		

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	LeBourdonnec, B. et al.; Synthesis and Pharmacological Evaluation of New Pyrazolidine-3,5-diones as AT ₁ Angiotensin II Receptor Antagonists, J. Med. Chem., Vol. 43, No. 14, 2000, pp 2685-2697; XP002259509

EXAMINER 	DATE CONSIDERED 1/20/06
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	